The discovery of RNAi dates back to the 1990s when researchers observed unexpected gene silencing in plants and fungi. In 1998, Andrew Fire and Craig Mello published a groundbreaking study ...

RNA interference (RNAi) is a fundamental cellular mechanism that regulates gene expression by inducing sequence-specific mRNA degradation. Researchers could utilize the RNAi as a powerful tool to ...

City Therapeutics, Inc., a biopharmaceutical company leading the future of RNA interference (RNAi)-based medicine, presented ...

Nearly 1.3 billion adults around the world have clinically high blood pressure, many of whom may be unaware that they are living with this condition. Nearly 1.3 billion adults around the world have ...

RNA interference (RNAi) therapeutics have garnered significant attention in clinical research due to their potential for treating various diseases, including genetic disorders, viral infections and ...

Arrowhead Pharmaceuticals’ RNA interference (RNAi) therapeutic lowered triglycerides in patients with a rare metabolic disease that prevents the body from breaking down fats during a phase 3 trial.

A new possibility for managing cardiovascular disease through RNA interference (RNAi) gene therapies. As cardiovascular diseases continue to be the leading cause of death globally, this technology ...

Scientists at the University of California, Riverside have developed a new, RNA-based vaccine strategy that could be effective against just about any strain of a virus, and can be used safely even for ...

ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase ...

Aedes aegypti, commonly known as the yellow fever mosquito, is a highly adapted, invasive mosquito species recognized as a major global health threat that acts as the primary vector for several severe ...